drugset
drugset / Trial / NCT04276415

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

NCT04276415 ↗

Phase 1 Terminated 34 enrolled Daiichi Sankyo
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess the safety, efficacy, and pharmacokinetics of DS-6157a in participants with advanced gastrointestinal stromal tumors (GIST).

Timeline

Start
2020-05-08
Primary completion
2022-03-11
Completion
2022-03-11

Outcome

Outcome not reported

Stopped (Business): “The study was terminated due to a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-6157a Other / unclassified 1.6 mg/kg Intravenous

Indications

gastrointestinal stromal tumor